Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 64, Issue 8, 2005, Pages 1210-1213

  Husebye, E S ^a,c   Sthoeger, Z M ^b   Dayan, M ^a   Zinger, H ^a   Elbirt, D ^b   Levite, M ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN HOSPITAL   (Israel)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DOUBLE STRANDED DNA; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A;

ADULT; AMINO ACID SEQUENCE; ARTICLE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; POLYENDOCRINOPATHIES, AUTOIMMUNE; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX;

EID: 23444443656     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.029280     Document Type: Article

References (25)

1. Hahn BH. An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus. Philadelphia: Williams and Wilkins, 1993:69-76.
2. Winchester RJ. Systemic lupus erythematosus pathogenesis. In: Koopman W, ed. Arthritis and allied conditions. Birmingham, Alabama: Williams and Wilkins, 1996:1361-91.
3. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
4. Lefkowith JB, Gilkeson GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum 1996;39:894-903.
5. Sthoeger ZM, Tartakovsky B, Bentwich Z, Mozes E. Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome. J Clin Immunol 1993;13:127-38.
6. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001;57:496-500.
7. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003;30:985-92.
8. Loukkola J, Laine M, Ainiala H, Peltola J, Metsanoja R, Auvinen A, et al. Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study. J Clin Exp Neuropsychol 2003;25:145-51.
9. Reichlin M. Ribosomal P antibodies and CNS lupus. Lupus 2003;12:916-18.
10. Kurki P, Helve T, Dahl D, Virtanen I. Neurofilament antibodies in systemic lupus erythematosus. J Rheumatol 1986;13:69-73.
11. Williams RC, Sugiura K, Tan EM. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2004;50:1239-47.
12. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT. Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;7:1189-93.
13. Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 1986;319:774-6.
14. Skerry TM, Genever PG. Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci 2001;22:174-81.
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
16. Tan EM. Autoantibodies to nuclear antigens (ANA): their biology and medicine. Adv Immunol 1982;33:167-240.
17. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
18. Schnolzer M, Kent SB. Constructing proteins by dovetailing unprotected synthetic peptides: backbone-engineered HIV protease. Science 1992;256:221-5.
19. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
20. Mayer ML, Armstrong N. Structure and functional of glutamate receptor ion channels. Annu Rev Physiol 2004;66:161-81.
21. Scatton B. The NMDA receptor complex. Fundam Clin Pharmacol 1993;7:389-400.
22. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem 2003;49:1752-02.
23. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 1990;13:171-82.
24. Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2000;23:222-9.
25. Takahasni Y, Mori H, Mishina M, Watanabe M, Fujiwara T, Shimomura J, Aiba H. Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua. Neurology 2003;61:891-6.